THE CLINICAL EFFICACY OF SINGLE MORNING DOSES OF LEVODOPA METHYL-ESTER - DISPERSIBLE MADOPAR AND SINEMET PLUS IN PARKINSON DISEASE

被引:41
作者
STEIGER, MJ [1 ]
STOCCHI, F [1 ]
BRAMANTE, L [1 ]
RUGGIERI, S [1 ]
QUINN, NP [1 ]
机构
[1] UNIV ROME LA SAPIENZA, DEPT CLIN SCI, NEUROL CLIN 1, I-00185 ROME, ITALY
关键词
PARKINSON DISEASE; LEVODOPA METHYL ESTER; DISPERSIBLE MADOPAR;
D O I
10.1097/00002826-199212000-00007
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
For many patients with Parkinson disease and levodopa-related motor fluctuations, the latency to onset of action of a single dose of a levodopa preparation may be both long and variable, In an effort to find a more rapidly acting and reliable preparation of levodopa, we therefore studied the efficacy of single doses of an oral solution of 250 mg of levodopa methyl ester (ME) with benserazide, 50 mg and of a molar equivalent dose of dispersible Madopar (DM) (50/200) in 13 patients in the fasting state after overnight drug withdrawal. The response of seven of these patients was compared to that after two Sinemet 25/100. The latency to "on" was equally fast with ME and DM, and significantly faster than after standard Sinemet. The duration of "on" was similar with all three. Because of this more rapid relief of "off" periods, both ME and DM offer a potential clinical advantage over standard preparations of levodopa.
引用
收藏
页码:501 / 504
页数:4
相关论文
共 10 条
[1]   BIOAVAILABILITY AND ACCEPTABILITY OF A DISPERSIBLE FORMULATION OF LEVODOPA-BENSERAZIDE IN PARKINSONIAN-PATIENTS WITH AND WITHOUT DYSPHAGIA [J].
BAYER, AJ ;
DAY, JJ ;
FINUCANE, P ;
PATHY, MSJ .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1988, 13 (03) :191-194
[2]   L-DOPA METHYL-ESTER - A CANDIDATE FOR CHRONIC SYSTEMIC DELIVERY OF L-DOPA IN PARKINSONS-DISEASE [J].
COOPER, DR ;
MARREL, C ;
TESTA, B ;
VANDEWATERBEEMD, H ;
QUINN, N ;
JENNER, P ;
MARSDEN, CD .
CLINICAL NEUROPHARMACOLOGY, 1984, 7 (01) :89-98
[3]   ON-OFF FLUCTUATIONS IN PARKINSONS-DISEASE - A CLINICAL AND NEURO-PHARMACOLOGICAL STUDY [J].
HARDIE, RJ ;
LEES, AJ ;
STERN, GM .
BRAIN, 1984, 107 (JUN) :487-506
[4]   LEVODOPA METHYL-ESTER TREATMENT OF PARKINSONS-DISEASE [J].
JUNCOS, JL ;
MOURADIAN, MM ;
FABBRINI, G ;
SERRATI, C ;
CHASE, TN .
NEUROLOGY, 1987, 37 (07) :1242-1245
[5]   MOOD SWINGS ASSOCIATED WITH THE ON-OFF PHENOMENON IN PARKINSONS-DISEASE [J].
NISSENBAUM, H ;
QUINN, NP ;
BROWN, RG ;
TOONE, B ;
GOTHAM, AM ;
MARSDEN, CD .
PSYCHOLOGICAL MEDICINE, 1987, 17 (04) :899-904
[6]   DYSTONIA IN PARKINSONS-DISEASE - CLINICAL AND PHARMACOLOGICAL FEATURES [J].
POEWE, WH ;
LEES, AJ ;
STERN, GM .
ANNALS OF NEUROLOGY, 1988, 23 (01) :73-78
[7]  
QUINN NP, 1986, LANCET, V1, P1366
[8]  
RUGGIERI S, 1989, LANCET, V2, P45
[9]   THE CLINICAL EFFICACY OF ORAL LEVODOPA METHYL-ESTER SOLUTION IN REVERSING AFTERNOON OFF PERIODS IN PARKINSONS-DISEASE [J].
STEIGER, MJ ;
STOCCHI, F ;
CARTA, A ;
RUGGIERI, S ;
AGNOLI, A ;
QUINN, NP ;
MARSDEN, CD .
CLINICAL NEUROPHARMACOLOGY, 1991, 14 (03) :241-244
[10]  
Sweet R D, 1974, Adv Neurol, V5, P331